Other languages Achieve Life Sciences, Inc.

Equities

ACHV

US0044685008

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
5.41 ^USD	0.00%		+8.20%	+31.31%

May. 13	Oppenheimer Adjusts Achieve Life Sciences Price Target to $11 From $18, Maintains Outperform Rating	MT
May. 09	Transcript : Achieve Life Sciences, Inc., Q1 2024 Earnings Call, May 09, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Achieve Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
Achieve Life Sciences, Inc. Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine	May. 06
Achieve Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Achieve Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 28
Achieve Life Sciences, Inc. Announces Data from Cytisinicline ORCA Program to Be Presented at the 2024 Society for Research on Nicotine and Tobacco Annual Meeting	Mar. 20
Sector Update: Health Care Stocks Decline Late Afternoon	Feb. 29
Sector Update: Health Care	Feb. 29
Achieve Life Sciences Agrees on Safety Exposure Data for Smoking Cessation Medication as Part of NDA	Feb. 29
Top Midday Decliners	Dec. 12
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%	Dec. 12
Investors Await Inflation Data, Look to Last Fed Meeting of Year as US Futures Rise Slightly in Tuesday's Premarket	Dec. 12
Top Premarket Decliners	Dec. 12
Achieve Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Achieve Life Sciences, Inc. Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting	23-09-11
Achieve Life Sciences, Inc. Announces Positive Topline Results from A Second Phase 3 ORCA-3 Trial	23-08-14
Achieve Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Achieve Life Sciences, Inc. Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association	23-07-11
Achieve Life Sciences Inc Provides Information to Shareholders	23-06-09
Achieve Life Sciences Reports Positive Topline Data From Trial of Cytisinicline; Shares Rise Pre-Bell	23-05-23
Achieve Life Sciences, Inc. Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial	23-05-23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Achieve Life Sciences, Inc.

Equities

ACHV

US0044685008

Other languages

Filters